Abstract

Enhanced activity of a pluronic F127 formulated Pin1 inhibitor for ovarian cancer therapy

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Palliative therapy in advanced ovarian cancer: balancing patient expectations, quality of life and cost.
Catherine Doyle ... Amita Patnaik
Anti-cancer drugs | VOL. 9
Catherine Doyle, et. al.Catherine Doyle ... Amita Patnaik
01 Nov 1998
Endocrine therapy in advanced high-grade ovarian cancer: real-life data from a multicenter study and a review of the literature.
Marine Aubert ... Mathilde Cancel
The oncologist | VOL. -
Marine Aubert, et. al.Marine Aubert ... Mathilde Cancel
20 May 2024
Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
Katherine C Kurnit ... Shannon N Westin
Current treatment options in oncology | VOL. 19
Katherine C Kurnit, et. al.Katherine C Kurnit ... Shannon N Westin
15 Nov 2018
The role of maintenance therapy and novel taxanes in ovarian cancer
David Cella ... J Tate Thigpen
Gynecologic Oncology | VOL. 102
David Cella, et. al.David Cella ... J Tate Thigpen
07 Feb 2006
View more papers

More From: Journal of Drug Delivery Science and Technology

Paper Title
Journal
Date
Author
Editorial Board
-
Journal of Drug Delivery Science and Technology | VOL. 96
--
01 Jun 2024
Graphical Abstract TOC
-
Journal of Drug Delivery Science and Technology | VOL. -
--
01 Jun 2024
Ameliorative delivery of docetaxel and curcumin using PEG decorated lipomers: A cutting-edge in-vitro/ in-vivo appraisal
Imran Tariq ... Udo Bakowsky
Journal of Drug Delivery Science and Technology | VOL. 97
Imran Tariq, et. al.Imran Tariq ... Udo Bakowsky
23 May 2024
Nanoparticles for the management of osteoarthritis: An overview
Priyanka Prabhu
Journal of Drug Delivery Science and Technology | VOL. 97
Priyanka PrabhuPriyanka Prabhu
23 May 2024
View more papers